# What the MERIT Act Actually Does

This bill changes how Medicare decides whether to cover new drugs and biological treatments. Right now, when Medicare evaluates whether a medication should be covered, they can make decisions about entire categories or classes of similar drugs all at once. The MERIT Act says that instead, Medicare must evaluate each individual drug or biological treatment on its own merits, one by one, rather than grouping them together.

To understand why this matters, imagine Medicare is deciding whether to cover a new type of cancer drug. Under current rules, they might evaluate all similar cancer drugs as a group and make one coverage decision that applies to all of them. Under this bill, Medicare would have to look at each specific cancer drug individually and decide whether that particular drug should be covered based on its own evidence and effectiveness. This could mean some drugs in the same family get covered while others don't, depending on what the evidence shows for each one.

The practical impact is that this could potentially speed up coverage for individual drugs that have strong evidence supporting them, since they won't be held up by decisions about their entire drug class. However, it also means more individual review processes, which could take more time and resources overall. For patients, this might mean faster access to certain medications if their specific drug gets approved, but it could also create confusion since similar drugs might have different coverage statuses. Insurance companies and drug manufacturers will likely need to navigate more complex coverage rules, and Medicare will need to conduct more individual evaluations rather than making broader category decisions.

MERIT Act

Buchanan, Vern

Mandating Exclusive Review of Individual Treatments (MERIT) Act This bill specifies that coverage determinations for drugs and biologics under Medicare must be made with respect to each drug or biologic, rather than with respect to a class of drugs or biologics.